Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded to Overweight from Equal-weight at Morgan Stanley as the brokerage ...

Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Learn more about whether Arcellx Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on AAII's A+ Investor ...

Learn more about whether ACADIA Pharmaceuticals Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on ...

We’re finally moving towards a causality-based nosology for psychiatry: specific symptoms with defined biological ...

周四，Morgan Stanley将Centessa Pharmaceuticals (NASDAQ:CNTA)的评级从持平上调至增持，并将目标价从之前的11美元大幅提高至26美元。这一估值变化是基于该公司ORX750研究的中期Phase 1结果。研究表明，该药物进入Phase 2开发阶段的轨迹明确，并暗示作为嗜睡症治疗方法的orexin 2受体的风险概况有所降低。

People with this difficult-to-detect sleep disorder can go undiagnosed for years and suffer from stigma. World Narcolepsy Day ...

Centessa Pharmaceuticals (CNTA) has received a new Buy rating, initiated by B.Riley Financial analyst, Mayank Mamtani. Mayank Mamtani has given ...

Dr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...

Researchers from Rutgers and Princeton universities will use a $16 million federal grant award to collaborate on several ...

TAK-861 is an investigational oral orexin receptor 2 (OX2R) selective-agonist desi OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2024--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion ...